IBC Generium is granted an exclusive license for other territories, and also has the right to an exclusive license for Russia and CIS states...Cardiome Pharma Corp., of Vancouver, British Columbia, said its board adopted an advance notice policy regarding the nomination of directors, establishing a deadline and written process by which registered or beneficial holders of the company's common shares (NASDAQ:CRME) must submit nominations to the company prior to an annual or special shareholder

DBV will conduct all preclinical work, up to proof-of-concept studies using Viaskin and Stallergenes' aeroallergens...In addition to RA and Crohn's, the pharma may develop GLPG0634 in psoriasis, irritable bowel syndrome and lupus, mirroring the path by which the label on its blockbuster Humira (adalimumab) was expanded beyond RA

DBV will conduct all preclinical work, up to proof-of-concept studies using Viaskin and Stallergenes' aeroallergens

turned its attention to other candidates in its pipeline...continue to view shares as undervalued based on the >$1B potential of ISIS-SMN-Rx, as well as the promise of ISIS-TTR-Rx and Isis' 20+ other pipeline candidates," he wrote...Jefferies Group LLC analyst Thomas Wei wrote in a research note that the company is valued entirely on Nuedexta sales, but "we could see upside from new indications and await data from ongoing proof-of-concept studies of AVP-923 in

Addex Therapeutics SA, of Geneva, said regulatory authorities in the Netherlands gave approval to start in the first half of this year a Phase I study of ADX71441, a GABA-B receptor positive allosteric modulator, for Charcot-Marie-Tooth1A (CMT1A) neuropathy and other disease indications...for the Brisbane, Australia-based company's Diversity Scanning Array (DSA) and Versatile Assembly on Stable Templates (VAST) technologies in a deal worth up to $240 million in milestones, plus other payments

Galapagos said it intends to start a proof-of-concept study in ulcerative colitis patients in the second quarter...In other news, GSK recently agreed to a nonexclusive material transfer, patent and know-how license deal with the Health Protection Agency (HPA) for the development and manufacture of a next-generation polio vaccine

Astellas Pharma Inc., of Tokyo, and Nagasaki University signed a collaborative research agreement to discover new drugs for the treatment of neglected tropical diseases (NTDs) caused by dengue virus...In separate news, Astellas signed a deal to access the TSUBAME2.0 supercomputer at the Tokyo Institute of Technology to discover candidates for NTDs caused by dengue virus...In other news, The Nasdaq OMX Stockholm's listing committee approved the listing of NeuroVive's shares

Astellas Pharma Inc., of Tokyo, said the European Commission approved expanded options for pre-treatment prior to use of Qutenza (8 percent capsaicin patch...Medigene's partner, Nordic Pharma Group, of Paris, is planning to launch Veregen in the Czech Republic, Poland, Hungary and Slovakia this year, upon conclusion of the reimbursable price-fixing procedure by the responsible authority...The IMODI project, which brings together big pharma firms including Paris-based Sanofi SA and Ipsen SA, along with

The IMODI project, which brings together big pharma firms including Paris-based Sanofi SA and Ipsen SA, along with biotechs such as Transgene SA, of Illkirch, France, is designed to make the selection of new effective treatments to combat eight cancer pathologies easier...That news "shocked the Street," according to Roth Capital Partners analyst Joseph Pantginis...Investors took the news hard, sending shares of Spectrum (NASDAQ:SPPI) falling $4.64, or 37.3 percent, to close Wednesday at $7.79

Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus, when other alternatives are not suitable...In other news, Elan said its Tysabri (natalizumab) restructuring transaction is

Celtic Therapeutics Management LLLP, of New York, changed its name to Auven Therapeutics Management LLLP to overcome confusion related to other Celtic entities...Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by

The companies will target development of drugs to treat topical ophthalmic diseases, including ocular allergy, dry eye and other inflammatory eye conditions...Araxes Pharma LLC, of San Diego, said it inked an exclusive arrangement with Janssen Biotech Inc., a unit of New Brunswick, N.J.-based Johnson & Johnson, to develop first-in-class therapeutics against a certain cancer target...Under the terms, Araxes will advance its program through Phase I to clinical proof of concept, after which Janssen will

At all doses tested, ALX-0061 was well tolerated and the safety profile compared favorably to data reported for other biological DMARDs...To date, almost 50 percent of planned patients have been enrolled in about 30 European centers...In both studies the JE vaccine was shown to be highly immunogenic in children/adolescents age 2 months to younger than 18 years with a safety profile comparable to pediatric vaccines licensed for other diseases

The companies partnered last year in a potential $200 million deal giving Avanir worldwide rights to AVP-786 and other deuterium-modified dextromethorphan compounds. (See BioWorld Today, March 1, 2012...Dyax Corp., of Burlington, Mass., and CVie Therapeutics, of Hong Kong, a subsidiary of Lee's Pharmaceutical Holdings Ltd., entered a deal to develop and commercialize Dyax's Kalbitor (ecallantide) for hereditary angioedema and other angioedema indications in China, Hong Kong and Macau...Zealand Pharma

Bone Medical Ltd., of Bentley, Australia, reported that its product candidate BN006 was found in a proof-of-concept study to reduce inflammation in a model of collagen antibody-induced arthritis...Cerulean Pharma Inc., of Cambridge, Mass., said preclinical data showed that CRLX101 in combination with Avastin (bevacizumab, Roche AG) inhibited tumor growth and improved survival vs...Lee's will have an option to negotiate for commercial rights in China

to test AXL1717, an oral small-molecule insulin-like growth factor 1 receptor inhibitor, in patients with malignant astrocytomas, a type of brain tumor...In other news, Novartis said the FDA approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia

Through a two-year collaboration, AstraZeneca will add 250,000 high-quality compounds to LDC's internal screening collection to pursue projects in the areas of oncology, neuroscience, respiratory and inflammation, cardiovascular, gastrointestinal and infection research...AstraZeneca then will have a preferred right to obtain a license for preclinical and clinical development and commercialization

The goal is for Amakem to develop candidates with in vivo proof of concept in appropriate models of IBD, as well as to obtain clear indications for the disease-modifying properties of those molecules...In other news, Evotec said it expanded its collaboration with MedImmune, part of London-based AstraZeneca plc, after hitting a key milestone

The Merck expansion grants the big pharma further access to Adimab's technology to discover and optimize fully human antibody candidates, including potentially bispecific antibody candidates, across all disease areas...Under the terms, Daiichi will pay Amplimmune an undisclosed option fee and provide more than $50 million to reimburse past and planned R&D costs, including funding for future development through a Phase II proof-of-concept study